Hadasit Bio Holdings (HBL) operates under a unique business model that combines the Hadassah hospital as a source of world class innovation (intellectual property) and facilities, with the management expertise, funding and liquidity associated with a public listing.
With this vehicle, private and institutional investors can participate in the creation of value based on these unique assets. To date, over $30 M have been raised, 8 companies have been funded and 3 compounds are in the midst of clinical trials, some with the backing of large multinationals.
The HBL business model along with the medical excellence and cutting edge research that emerges from the Hadassah medical centers has attracted great interest around the world, including institutional as well as private investors.
We are happy to provide an easy and convenient investment channel for our international investors:
In the USA, shares of HBL (OTCBB: HADSY) can now be purchase through your local broker. HBL has established an American Depository Receipt (ADR) through BNY Mellon where every ADR represents 20 shares on the TASE.
Shares of HBL (TASE: HDST) can also be purchased directly on the Tel Aviv Stock Exchange (Security No.; 1095405).
US Investors:
KCSA Strategic Communications,
Jeff Corbin/Rob Fink
Email: rfink@kcsa.com
Phone: 212-896-1206
| 
